drugset
drugset / Trial / NCT02795637

Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction

NCT02795637 ↗

Phase 1 Completed 44 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)

Timeline

Start
2016-05
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 8 mg Oral

Indications

attention deficit-hyperactivity disorder binge eating disorder